TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Comparison of Surgical Skin Preps During Cesarean Deliveries
Brief Summary: In women that undergo non-emergency cesarean delivery, we are comparing the skin preparation solutions for best outcome of surgical site infection. The three different solutions are: Group 1: Iodine povidone based skin preparation solution. Group 2: Chlorhexidine based skin preparation solution or Group 3: Combination usage of iodine povidone and chlorhexidine based skin preparation solutions. Women are prospectively randomized to one of the three groups and followed until thier postpartum visit at 6-8 weeks following delivery.


Options:
A: Inclusion Criteria:

* Scheduled low transverse cesarean section (can be primary or repeat)
* Term gestation ≥ 37 weeks

Exclusion Criteria:

* Allergy to either antiseptic
* Rupture of amniotic membranes
* Preterm gestation
* Active labor
* Emergency or unscheduled cesarean sections
* Infection diagnosis on admission
* Vaginal infection or any treatment of vulvovaginitis in prior 7 days
* Patients under the age of 18 years
B: Inclusion Criteria:

* Gestational age \> 37 weeks 0/7 days
* Non-emergency indication for cesarean

Exclusion Criteria:

* Urogenital tract infection within 2 weeks prior to surgery
* Chronic oral or injectable steroid use (\> 2 weeks)
* Emergency cesarean delivery
* Participation in another research study
C: Intervention Group (vaginal preparation)

Inclusion Criteria:

* Pregnant women admitted for cesarean delivery
* Gestational age greater than or equal to 34 weeks

Exclusion Criteria:

* Rupture of membranes or active labor
* Chorioamnionitis (prior to enrollment)
* Recent (within 4 weeks) antibiotic exposure
* Maternal HIV infection or immunocompromised state
* Known allergy to shellfish, iodine, or chlorhexidine
D: Inclusion Criteria:

* Women at \> 24 weeks gestation who are admitted in labor or admitted for induction of labor at Mount Sinai Hospital

Exclusion Criteria:

* Allergy to chlorhexidine
* Unplanned or emergency cesarean section
* Women at \<24 weeks gestation
* Estimated fetal weight \<500 grams
* Fetal face presentation regardless of gestational age.

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: 7% Hypertonic Saline for Acute Bronchiolitis: A Randomized Controlled Trial
Brief Summary: Research suggests that hypertonic saline may improve mucous flow in infants with acute bronchiolitis. Data suggest a trend favoring reduced length of hospital stay and improved pulmonary scores with increasing concentration of nebulized solution to 3% and 5% saline as compared to 0.9% saline mixed with epinephrine. To our knowledge, 7% hypertonic saline has not been previously investigated. OUr hypothesis was that 7% hypertonic saline would improve bronchiolitis severity scores and admission rate.


Options:
A: Inclusion Criteria:

* Patients age 6 weeks to ≤ 18 months
* Diagnosed with bronchiolitis (defined as viral respiratory illness and first episode of wheeze)
* BSS score of ≥ 4

Exclusion Criteria:

* A previous history of wheezing;
* diagnosis of asthma;
* any use of bronchodilators within 2 h of presentation
* gestational age ≤ 34 weeks
* history of congenital heart disease
* chronic pulmonary or chronic renal disease
* oxygen saturation of ≤ 85% at the time of recruitment
* severe disease requiring intensive care unit admission
* inability to obtain informed consent
B: Inclusion Criteria:

* Patients 0-12 months of age admitted to the hospital with a diagnosis of bronchiolitis.

Exclusion Criteria:

* status asthmaticus
* chronic cardiopulmonary disease
* Trisomy 21
* immunodeficiency or transplant recipient
* neuromuscular disease
* admission directly to the intensive care unit
* previous use of nebulized hypertonic saline less than 12 hours prior to presentation
* previous enrollment in the study in the 72 hours prior to presentation
C: Inclusion Criteria:

1. \< 24 months.
2. presenting to ER or outpatient department with moderately severe viral bronchiolitis defined as:

   1. history of viral upper respiratory tract infection within previous 7 days, plus
   2. presence of wheezing and/or crackles on chest auscultation, plus
   3. Respiratory Distress Assessment Instrument (RDAI, appendix B) score \> 4 (of 17) or transcutaneous oxygen saturation (SaO2) \< 94% in room air.

Patient exclusion criteria:

1. history of immunodeficiency or chronic cardiopulmonary disease (other than past history of wheezing).
2. critical illness at presentation.
3. use of nebulized HS within previous 12 hr.
4. prematurity (gestational age \< 34 weeks).
D: Inclusion Criteria:

* clinical diagnosis of viral bronchiolitis
* between November and April

Exclusion Criteria:

* prematurity \< 34 weeks
* chronic lung disease
* congenital heart disease
* history of wheezing, asthma or albuterol use
* tracheostomy status
* need for intensive care of assisted ventilation

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: 7% Hypertonic Saline for Acute Bronchiolitis: A Randomized Controlled Trial
Brief Summary: Research suggests that hypertonic saline may improve mucous flow in infants with acute bronchiolitis. Data suggest a trend favoring reduced length of hospital stay and improved pulmonary scores with increasing concentration of nebulized solution to 3% and 5% saline as compared to 0.9% saline mixed with epinephrine. To our knowledge, 7% hypertonic saline has not been previously investigated. OUr hypothesis was that 7% hypertonic saline would improve bronchiolitis severity scores and admission rate.


Options:
A: Inclusion Criteria:

* Age 6 weeks through 12 months
* First moderate to severe episode of acute viral bronchiolitis (history of viral upper respiratory tract infection plus wheezing and/or crackles on chest auscultation with respiratory distress ).
* Admission in Emergency Department
* Parental/guardian permission (informed consent)

Exclusion Criteria:

* prematurity \< 37 weeks
* artificial ventilation in the neonatal period
* Chronic lung or heart disease
* history of immunodeficiency
* past use of nebulized HS
* initial need for intensive care of assisted ventilation
* Non-French speaking parent/guardian
B: Inclusion Criteria:

* clinical diagnosis of viral bronchiolitis
* between November and April

Exclusion Criteria:

* prematurity \< 34 weeks
* chronic lung disease
* congenital heart disease
* history of wheezing, asthma or albuterol use
* tracheostomy status
* need for intensive care of assisted ventilation
C: Inclusion Criteria:

* Patients age 6 weeks to ≤ 18 months
* Diagnosed with bronchiolitis (defined as viral respiratory illness and first episode of wheeze)
* BSS score of ≥ 4

Exclusion Criteria:

* A previous history of wheezing;
* diagnosis of asthma;
* any use of bronchodilators within 2 h of presentation
* gestational age ≤ 34 weeks
* history of congenital heart disease
* chronic pulmonary or chronic renal disease
* oxygen saturation of ≤ 85% at the time of recruitment
* severe disease requiring intensive care unit admission
* inability to obtain informed consent
D: Inclusion Criteria:

* Previously healthy infants under 1 year of age
* Admitted to hospital with a clinical diagnosis of acute bronchiolitis, following the UK definition of an infant with an apparent viral respiratory tract infection associated with airways obstruction manifest by hyperinflation, tachypnoea and subcostal recession with widespread crepitations on auscultation
* Requiring supplemental oxygen therapy on admission

Exclusion Criteria:

* Wheezy bronchitis or asthma - children with an apparent viral respiratory infection and wheeze with no or occasional crepitations
* Previous lower respiratory tract infections
* Risk factors for severe disease \[gestation \<32 weeks, immunodeficiency, neurological and cardiac conditions, chronic lung disease\]
* Subjects where the carer's English is not fluent and translational services are not available
* Requiring admission to high dependency or intensive care units at the time of recruitment

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: High Flow Therapy vs Hypertonic Saline in Bronchiolitis Treatment. Randomized Controlled Trial
Brief Summary: The purpose of this study is to demonstrate that heated, humidified, high-flow nasal cannula (HHHFNC) is superior to hypertonic saline solution (HSS) in the treatment of moderate acute viral bronchiolitis in infants in improving respiratory distress and comfort and reducing length of hospital stay (LOS) and admission to Pediatric Intensive Care Unit (PICU).


Options:
A: Inclusion Criteria:

Children of either sex, aged 0-4 years, with severe/very severe pneumonia (per WHO guidelines) and hypoxaemia (SpO2 \< 90%) will be included in our study in the ARI Unit of the Longer Stay Ward (LSW), High Dependency Unit HDU, and ICU unit of Dhaka Hospital of ICDDR,B.

Exclusion Criteria:

Children with uncorrected cyanotic CHD, hypercapnoea (PCO2 \> 65 mm of Hg), status asthmaticus and upper-airway obstruction, and those for whom inform consent can't be secured from their parents/ care-givers. Children with features (any two of three criteria given below) of "treatment failure" on admission (before enrollment into the study) will also be excluded from the study. Arterial blood gas analysis will be performed to check the exclusion criteria
B: Inclusion Criteria:

* Children aged 6 months or less
* Moderate (Respiratory Distress Assessment Instrument score of 4 or greater) viral bronchiolitis (as defined by McConnockie)
* Meeting Admission criteria

Exclusion Criteria:

* History of prematurity
* Chronic lung disease
* Cystic fibrosis
* Congenital heart disease
* Neuromuscular disease
* Airway anomalies
* Immunodeficiency
* Those requiring immediate intubation and ventilation.
C: Inclusion Criteria:

* Clinical diagnosis of bronchiolitis defined as the first viral episode of respiratory distress before 2 years of aging, presenting with rhinitis, tachypnea, cough, wheezing, prolonged expiratory time, crackles and use of accessory muscles, with or without fever, with or without infiltrate on the chest X ray
* bronchiolitis severity Wang modified score ≥ 10

Exclusion Criteria:

* recurrent wheezing
* heart disease
* chronic lung disease
* neuromuscular disease
* primary diagnosis was not bronchiolitis (pneumonia, pertussis)
* critically ill infants who had an immediate need of intubation
D: Inclusion Criteria:

* 1) receiving NCPAP ventilatory support at \> 72 hrs. of age and 2) requiring FiO2 21-50% on NCPAP.

Exclusion Criteria:

* FiO2 \>50%, presence of pneumothorax or pleural effusion, anatomical abnormalities of the airway, lungs, or esophagus, or cyanotic congenital heart defect.

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: High Flow Therapy vs Hypertonic Saline in Bronchiolitis Treatment. Randomized Controlled Trial
Brief Summary: The purpose of this study is to demonstrate that heated, humidified, high-flow nasal cannula (HHHFNC) is superior to hypertonic saline solution (HSS) in the treatment of moderate acute viral bronchiolitis in infants in improving respiratory distress and comfort and reducing length of hospital stay (LOS) and admission to Pediatric Intensive Care Unit (PICU).


Options:
A: Inclusion Criteria:

* Previously healthy infants under 1 year of age
* Admitted to hospital with a clinical diagnosis of acute bronchiolitis, following the UK definition of an infant with an apparent viral respiratory tract infection associated with airways obstruction manifest by hyperinflation, tachypnoea and subcostal recession with widespread crepitations on auscultation
* Requiring supplemental oxygen therapy on admission

Exclusion Criteria:

* Wheezy bronchitis or asthma - children with an apparent viral respiratory infection and wheeze with no or occasional crepitations
* Previous lower respiratory tract infections
* Risk factors for severe disease \[gestation \<32 weeks, immunodeficiency, neurological and cardiac conditions, chronic lung disease\]
* Subjects where the carer's English is not fluent and translational services are not available
* Requiring admission to high dependency or intensive care units at the time of recruitment
B: Inclusion Criteria:

* Children aged 6 months or less
* Moderate (Respiratory Distress Assessment Instrument score of 4 or greater) viral bronchiolitis (as defined by McConnockie)
* Meeting Admission criteria

Exclusion Criteria:

* History of prematurity
* Chronic lung disease
* Cystic fibrosis
* Congenital heart disease
* Neuromuscular disease
* Airway anomalies
* Immunodeficiency
* Those requiring immediate intubation and ventilation.
C: Inclusion Criteria:

* Patients 0-12 months of age admitted to the hospital with a diagnosis of bronchiolitis.

Exclusion Criteria:

* status asthmaticus
* chronic cardiopulmonary disease
* Trisomy 21
* immunodeficiency or transplant recipient
* neuromuscular disease
* admission directly to the intensive care unit
* previous use of nebulized hypertonic saline less than 12 hours prior to presentation
* previous enrollment in the study in the 72 hours prior to presentation
D: Inclusion Criteria:

* Patients age 6 weeks to ≤ 18 months
* Diagnosed with bronchiolitis (defined as viral respiratory illness and first episode of wheeze)
* BSS score of ≥ 4

Exclusion Criteria:

* A previous history of wheezing;
* diagnosis of asthma;
* any use of bronchodilators within 2 h of presentation
* gestational age ≤ 34 weeks
* history of congenital heart disease
* chronic pulmonary or chronic renal disease
* oxygen saturation of ≤ 85% at the time of recruitment
* severe disease requiring intensive care unit admission
* inability to obtain informed consent

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Is Multifactorial Nutritional Treatment for Undernutrition in Older Adults in Primary Care Cost-effective?
Brief Summary: The hypothesis is that there is a profit potential by implementing a multifactorial nutritional intervention among frail elderly since this will result in an improved nutritional status, functional capacity and improved quality of life.


Options:
A: Inclusion Criteria:

* all patients admitted to the study area on a participating elderly care ward

Exclusion Criteria:

* none.
B: Inclusion Criteria:

* Screening for nutritional risk

Exclusion Criteria:

* terminal condition or do not wish to participate
C: On cluster level

Inclusion Criteria:

* nursing homes with at least 50 residents

Exclusion Criteria:

* other ongoing trial in the institution

On individual level

Inclusion Criteria:

* all residents within a cluster are eligible to participate in the study

Exclusion Criteria:

* diagnoses of schizophrenia, schizoaffective psychosis, or other forms of primary psychosis
* respite care
D: Inclusion Criteria:

* 65 Years or older permanently living in care homes for older people
* One or more falls in the previous year.
* Foot problem that is within the scope of podiatry care

Exclusion Criteria:

* Residents who are terminally unwell or too frail to be included
* Residents who are only able to mobilise with the use of a wheelchair
* Temporary residents (for example, those in respite care)
* Unable to provide informed consent
* Lower limb Amputees

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: N/A
Brief Summary: Background:

Aim:

Clinical evaluation of the effectiveness of two different polyethylene glycol doses for the maintenance treatment of functional constipation in children.

Study design:

Randomized, open-label trial.

Randomized, double-blind, placebo controlled trial.


Options:
A: Inclusion Criteria:

* out-patients children with diagnosis of functional constipation or have faecal impaction on medical history and physical examination

Exclusion Criteria:

* children with organic causes for defecation disorders, such as Hirschsprung disease, spina bifid, hypothyroidism, or other metabolic or renal abnormalities;
* Children receiving medication influencing gastrointestinal motility;
* Children with suspected gastrointestinal obstruction or stenosis
B: Inclusion Criteria:

* Chronic constipation (defined as at least 3 months of less than 2 bowel movements (BMs) per week and/or one of the following symptoms : hard stool, painful defecation, encopresis)
* Constipation previously treated by dietary advice (high fiber diet) for at least two weeks without efficacy

Exclusion Criteria:

* Organic bowel diseases
* Suspected GI obstruction
* History of GI surgery
C: Inclusion Criteria:

* Childhood functional constipation
* 6 months to \<16 years of age
* Male or female
* For females of childbearing potential (after menarche): negative pregnancy test
* Moderately severe to severe constipation, defined as stool frequency \<3 stools/week
* Informed consent signed by parent(s) or legal acceptable representative(s), after sufficient oral and written information before entering the study, to be documented by the investigators in the Case Report Form

Exclusion Criteria:

* Functional non-retentive fecal incontinence
* Known metabolic or endocrine disorders (s.a. hypothyroidism)
* Neurologic disorders (s.a. spina bifida or spinal cord anomaly)
* Hirschsprung's disease (congenital megacolon)
* Anal anomaly
* Gastrointestinal surgery
* Drug induced constipation
* Mental retardation
* Cerebral palsy
* Treatment with other laxatives
* Drugs influencing gastrointestinal function (e.g., cisapride, erythromicin, imodium)
* Prior bowel surgery, except appendectomy
* Earlier participation in this trial
* Concurrent participation in any other clinical trial
* Participation in any other clinical study 6 months prior to inclusion
* Any use of a Macrogol within 2 months prior to inclusion
D: Inclusion Criteria:

* age 1 - 18 age
* functional constipation according to the Rome III Criteria
* consent of parents or guardians of the child to participate and study

Exclusion Criteria:

* organic cause constipation (including surgeries within the lower GI tract)

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Targeted Screening of At-Risk Adults for Acute HIV-1 Infection
Brief Summary: In this research, the investigators want to see if early detection of HIV infection can be improved by testing young adults who seek urgent health care from pharmacies and healthcare facilities with symptoms similar to those people get with recent HIV infection.

Specific objectives:

1. What proportion of people presenting with these symptoms are HIV positive at the point of seeking urgent health care?
2. What proportion of those who test negative or where the result is unclear (one rapid test positive and one negative) at first rapid HIV testing, will test positive two weeks later?
3. What is the best way (SMS, phone call or home visit) to remind people to come for the second test after two weeks?
4. Will young adults who seek urgent health care for fever, body pains, diarrhoea or an STD from pharmacies or health facilities find it acceptable to be invited for an HIV-1 test at the time of health care seeking?

Hypotheses

1. Targeted screening for AHI among patients seeking health care for symptoms compatible with AHI or sexually transmitted disease (STD) will identify AHI cases in more than 1% of those screened.
2. Intense follow-up of patients evaluated for AHI will improve rates of repeat HIV-1 testing 2-4 weeks after initial health-care seeking, relative to standard practice (i.e., recommendation to return for testing on a given date).


Options:
A: Inclusion Criteria:

* the mother has access to a cell phone (either her own phone or the phone of a household member)
* the mother lives in the uptake area of the health center.

Exclusion Criteria:

* the mother does not have access to a mobile phone.
B: Inclusion Criteria:

* currently enrolled in the Cedar Project
* completed main Cedar Project Baseline questionnaire and attended at least one follow-up visit since 2009
* had not tested positive for HIV
* joined study in Vancouver or Prince George
* alive at initiation of Cedar Project mHealth study
C: Inclusion Criteria:

* symptom score of 2 or more: Confirmed fever (≥37.5 °C axillary), reported diarrhoea, or evidence of STD (variable score=2); reported body pains, or report of more than one sexual partners in past 2 months (variable score=1)
* resident in Mtwapa or Shanzu or planning to stay in Mtwapa for approximately 4 weeks duration
* willing to give locator information (including mobile phone number)
* negative or unknown HIV status

Exclusion Criteria:

* patients not meeting inclusion criteria
D: Inclusion Criteria:

* Aged 16-24
* Own a personal Android mobile phone
* Live in Tajikistan

Exclusion Criteria:

* Cannot read Tajik or Russian

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Should we Associate Dexamethasone and Ondansetron to Closed-loop Anesthesia to Reduce the Incidence of Postoperative Nausea and Vomiting After Bariatric Surgery?
Brief Summary: The investigators want to test if it is indicated to associate dexamethasone and ondansetron in obese patients having bariatric surgery under total intra-venous closed-loop anesthesia.


Options:
A: Inclusion Criteria:

* Patient undergoing laparoscopic gynecologic surgery.
* Patient who takes fentanyl based IV PCA
* ASA class I-II

Exclusion Criteria:

* allergy to aprepitant
* take another antiemetics before surgery
* decreased liver function
* psychological disease
* who cannot speak Korean
* take medicines that interacts with emend who do not agree to the study
B: Inclusion Criteria:

* Adult patients aged 18-75 years
* Scheduled for bariatric surgery under total intra-venous closed-loop anesthesia
* Apfel score equal or greater than 2
* Consenting to participate in the study

Exclusion Criteria:

* Pregnant, breast feeding women
* Allergy
* Contraindication to dexamethasone
* Contraindication to ondansetron
* Contraindication to propofol, remifentanil, morphine, ketoprofen
* Limit to the use of bispectral index
C: Inclusion Criteria:

* All patients undergoing breast surgery for carcinoma breast.
* Patients between ages 18 to 60 years.
* ASA I \\ II \\ III
* Patients weight between 40 and 70 kilograms.

Exclusion Criteria:

* Patient refusing consent
* Prophylactic anti emetic drug administration during intraoperative period
* Known case of prolonged QTc interval
* Known case decompensated cardiomyopathy
* Known case of cardiac arrhythmia or bundle branch block
* Case of congestive heart failure with left ventricular ejection fraction \<40%
* Abnormal serum level of potassium, calcium, magnesium
D: Inclusion Criteria:

* Patient over 18 and under 65 year-old
* Having a moderate to severe POVN (post operative vomiting and nausea) risk, meaning with at least two risk factors in the simplified Apfel score
* Outpatient surgery associated to a general anesthesia
* Patient having signed an informed consent- Patient having a social protection

Exclusion Criteria:

* Contraindication to Droperidol
* Contraindication to Ondansetron
* Patients usually treated with benzodiazepine or having been treated with benzodiazepine within 2 days prior to anesthesia
* Psychiatric and Neurodegenerative diseases
* Severe Anxiety
* Contraindication to general anesthesia or one of its components
* Allergy to propofol
* Inability to get informed (patient in an emergency situation, difficulties to understand)
* Patient under judicial protection
* Patient under tutorship or curatorship
* Pregnancy reported by the patient- Breastfeeding
* Patient in an exclusion period

Answer: B